Skip to Content

Plivensia Approval Status

Plivensia (sirukumab) is a human anti-interleukin-6 monoclonal antibody in development for the treatment of rheumatoid arthritis.

Development Status and FDA Approval Process for Plivensia

Aug  2, 2017FDA Advisory Committee Does Not Recommend Approval of Sirukumab for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Nov 16, 2016GSK Announces New Data from Phase III Studies of Sirukumab in Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Sep 23, 2016Janssen Submits Application Seeking Approval of Sirukumab in United States for Rheumatoid Arthritis
Jun  8, 2016GSK announces phase III study of sirukumab meets both co-primary endpoints in patients with rheumatoid arthritis
Dec 16, 2015GSK receives positive top-line results from sirukumab phase III programme supporting regulatory filings for rheumatoid arthritis in 2016
Nov 25, 2015GSK Announces Start of Phase III Study of Sirukumab in Giant Cell Arteritis
May 25, 2011Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.